Missouri Hemp THC Ban: Legal Challenges, Industry Impact & Consumer Rights

Executive Summary

Missouri's hemp-derived THC product ban, enacted in 2024, faces a federal constitutional challenge from industry plaintiffs alleging violations of interstate commerce and due process protections. The lawsuit, filed in July 2026 in the U.S. District Court for the Western District of Missouri, represents the latest escalation in a two-year conflict between Missouri's regulated cannabis market and the unregulated hemp-derived cannabinoid industry. Missouri banned sales of intoxicating hemp products containing delta-8 THC, delta-10 THC, THCA, and other psychoactive cannabinoids in September 2024, citing public health concerns and the need to protect the state's licensed marijuana market. The ban eliminated an estimated $200 million annual hemp-derived THC market operating in gas stations, smoke shops, and online retailers across Missouri. Industry groups argue the prohibition conflicts with the 2018 Farm Bill's legalization of hemp and discriminates against interstate commerce in favor of Missouri's in-state marijuana licensees. The case could establish precedent affecting similar regulatory conflicts in more than a dozen states where hemp-derived intoxicants compete with licensed cannabis markets.

Why This Matters

The Missouri hemp THC ban litigation affects thousands of retailers, millions of consumers, and the fundamental question of whether states can restrict federally legal hemp products to protect state-licensed marijuana markets. Missouri's adult-use marijuana program, approved by voters in November 2022 through Amendment 3, generated $1.2 billion in licensed sales during its first full year of operation in 2023. Licensed operators pay a 6% retail tax plus application and licensing fees totaling hundreds of thousands of dollars per facility. Meanwhile, hemp-derived THC products proliferated in unregulated retail channels with no age verification requirements, no testing mandates, and no taxation. The ban directly impacts an estimated 2,500 Missouri retailers that sold hemp-derived THC products before September 2024, according to the Missouri Hemp Trade Association. These retailers include independent smoke shops, CBD stores, gas station chains, and online sellers shipping into Missouri. Industry representatives estimate the prohibition eliminated 3,000 jobs in manufacturing, distribution, and retail of hemp-derived products statewide. For consumers, the ban restricts access to products that were widely available and often significantly cheaper than state-licensed marijuana. A 10mg delta-8 THC gummy typically retailed for $0.50-$1.00 in Missouri gas stations before the ban, compared to $3-$5 for a comparable 10mg delta-9 THC gummy from a licensed dispensary. An estimated 400,000 Missouri adults purchased hemp-derived THC products in 2023, according to market research firm BDSA. The litigation's outcome will influence regulatory approaches in states including Texas, Georgia, North Carolina, Tennessee, and Florida, where similar conflicts between hemp and marijuana markets have generated legislative debates. A ruling favoring the hemp industry could constrain state authority to regulate federally legal hemp derivatives. A ruling upholding Missouri's ban would provide a roadmap for other states seeking to eliminate hemp-derived intoxicants.

Background and History

The 2018 Farm Bill Creates Hemp Industry

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from the Controlled Substances Act and legalized cultivation of cannabis plants containing no more than 0.3% delta-9 THC by dry weight. The Farm Bill, codified at 7 U.S.C. § 1639o et seq., defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The law transferred regulatory authority over hemp from the Drug Enforcement Administration to the U.S. Department of Agriculture. States gained authority to submit regulatory plans for USDA approval. The legislation made no distinction between non-intoxicating hemp derivatives like CBD and intoxicating cannabinoids like delta-8 THC, provided they were derived from compliant hemp plants.

Delta-8 THC Market Emerges 2019-2021

Entrepreneurs discovered that delta-8 THC, a mildly psychoactive cannabinoid, could be synthesized from CBD extracted from legal hemp through chemical isomerization processes. Delta-8 THC occurs naturally in cannabis plants at concentrations below 1%, but manufacturers developed methods to convert CBD into delta-8 THC using acids, heat, and catalysts. The resulting products produced intoxicating effects similar to but reportedly milder than delta-9 THC, the primary psychoactive compound in marijuana. Delta-8 THC products appeared in smoke shops and gas stations across the United States beginning in 2019, with explosive growth in 2020 and 2021. The market expanded to include delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), and other semi-synthetic cannabinoids. Manufacturers also discovered that THCA, the non-intoxicating acid form of THC found in raw cannabis, could be extracted from hemp plants bred to contain high THCA but low delta-9 THC levels. When heated through smoking or vaping, THCA converts to psychoactive delta-9 THC. By 2022, the hemp-derived THC market reached an estimated $2 billion nationally, according to cannabis market research firm Brightfield Group. Products included gummies, vape cartridges, tinctures, and hemp flower marketed as "legal weed."

Missouri Legalizes Adult-Use Marijuana November 2022

Missouri voters approved Constitutional Amendment 3 on November 8, 2022, legalizing adult-use marijuana possession and sales with 53.1% support. The amendment, which took effect December 8, 2022, allowed adults 21 and older to possess up to three ounces of marijuana and cultivate up to six flowering plants for personal use. The measure directed the Missouri Department of Health and Senior Services to issue marijuana business licenses, prioritizing existing medical marijuana licensees for initial adult-use licenses. Amendment 3 imposed a 6% retail sales tax on adult-use marijuana in addition to standard state and local sales taxes. The constitutional amendment specified that marijuana tax revenue would fund expungement of prior marijuana convictions, veterans' services, and public defender offices. Missouri's adult-use marijuana sales launched February 3, 2023, generating $103 million in the first month. The amendment defined marijuana as "all parts of the plant genus Cannabis" but did not address hemp or hemp-derived products. This created a regulatory gap where intoxicating hemp products remained legal and unregulated while marijuana products faced strict testing, packaging, and taxation requirements.

Licensed Industry Demands Hemp Regulation 2023

Missouri marijuana licensees lobbied state legislators and regulators throughout 2023 to restrict hemp-derived THC products they characterized as untested, unregulated competition. Industry groups including the Missouri Cannabis Trade Association argued that hemp-derived intoxicants undermined the voter-approved regulatory framework and posed public health risks due to lack of testing requirements. Licensed operators pointed to laboratory testing showing some hemp-derived products contained heavy metals, pesticides, and residual solvents at levels that would fail marijuana testing standards. A June 2023 investigation by the Missouri Independent tested 12 delta-8 THC products purchased at gas stations and found five contained delta-9 THC levels exceeding the 0.3% legal limit for hemp, and three contained vitamin E acetate, a cutting agent linked to lung injuries. Hemp industry representatives countered that responsible manufacturers conducted voluntary testing and that problems stemmed from bad actors, not the products themselves. The Missouri Hemp Trade Association proposed a regulatory framework with age restrictions, testing requirements, and labeling standards as an alternative to prohibition.

Emergency Rule Bans Hemp THC Products September 2024

The Missouri Department of Health and Senior Services issued an emergency rule on September 1, 2024, prohibiting the manufacture, distribution, and sale of "intoxicating hemp products" containing delta-8 THC, delta-10 THC, THCA, and other psychoactive cannabinoids. The emergency rule, filed under Missouri Revised Statutes § 536.025, took effect immediately without the standard public comment period required for permanent regulations. The department justified the emergency action by citing "an immediate danger to the public health, safety or welfare" based on reports of adverse events associated with hemp-derived products and the lack of regulatory oversight. The rule defined intoxicating hemp products as any hemp-derived product "formulated to be consumed or used in a manner that induces intoxication" or containing "a total delta-9 THC concentration of more than 0.3% or any artificially derived or synthetically derived cannabinoid." The emergency rule provided a 30-day grace period, requiring retailers to remove banned products from shelves by October 1, 2024. Violations would constitute a Class A misdemeanor punishable by up to one year in jail and a $2,000 fine under Missouri Revised Statutes § 195.017.

Industry Challenges Rule in State Court October 2024

Hemp industry plaintiffs filed a lawsuit in Cole County Circuit Court on October 15, 2024, challenging the emergency rule as exceeding the department's statutory authority. The lawsuit, Missouri Hemp Trade Association v. Missouri Department of Health and Senior Services, argued that the department lacked authority to ban federally legal hemp products and that the emergency rule violated state administrative procedure requirements. The Cole County court issued a temporary restraining order on October 22, 2024, blocking enforcement of the ban pending a full hearing. However, the Missouri Supreme Court dissolved the restraining order on November 8, 2024, allowing the ban to take effect while litigation continued. The state high court ruled that the department had demonstrated sufficient evidence of immediate public health concerns to justify emergency rulemaking. The state court case remained pending through early 2026, with the department converting the emergency rule to a permanent regulation through the standard rulemaking process in January 2025.

Federal Lawsuit Filed July 2026

Hemp industry plaintiffs filed a new federal lawsuit on July 18, 2026, in the U.S. District Court for the Western District of Missouri, alleging the ban violates the Commerce Clause and Due Process Clause of the U.S. Constitution. The complaint, filed by a coalition of hemp manufacturers, retailers, and trade associations, argues that Missouri's prohibition discriminates against interstate commerce in federally legal hemp products to protect in-state marijuana licensees from competition. The federal lawsuit names the Missouri Department of Health and Senior Services and its director as defendants. Plaintiffs seek declaratory and injunctive relief preventing enforcement of the ban. The case was assigned to U.S. District Judge Brian C. Wimes.

Key Players

Missouri Department of Health and Senior Services

The Missouri Department of Health and Senior Services serves as the state's marijuana and hemp regulatory authority, responsible for licensing marijuana businesses and enforcing the hemp product ban. The department's Section for Medical Marijuana Regulation, established in 2018, oversees approximately 400 licensed marijuana facilities including cultivation centers, manufacturing facilities, and dispensaries. Director Paula Nickelson, appointed in 2023, defended the hemp ban as necessary to protect public health and the integrity of the regulated marijuana market. The department cited 47 reported adverse events associated with hemp-derived THC products in Missouri during 2023-2024, including hospitalizations for severe vomiting, psychosis, and seizures.

Missouri Cannabis Trade Association

The Missouri Cannabis Trade Association represents approximately 200 licensed marijuana businesses and lobbied aggressively for the hemp product ban. Executive Director Amy Moore testified before state legislators in 2024 that hemp-derived intoxicants represented unfair competition because they avoided the testing, packaging, and taxation requirements imposed on licensed marijuana. The association argued that the ban leveled the playing field and protected consumers from untested products. Licensed marijuana operators invested an estimated $500 million in Missouri facilities, equipment, and licensing fees, according to the association.

Missouri Hemp Trade Association

The Missouri Hemp Trade Association represents hemp farmers, processors, and retailers opposing the ban as federal preemption and economic overreach. President Jason Mitchell stated that the prohibition eliminated legitimate businesses to protect marijuana industry profits. The association proposed alternative regulatory frameworks including age restrictions, testing requirements, and potency limits as less restrictive alternatives to prohibition. The group estimates Missouri hemp farmers cultivated 8,000 acres of hemp in 2023, with approximately 40% of the crop destined for cannabinoid extraction.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a national hemp industry coalition, filed an amicus brief supporting the federal lawsuit and arguing that state bans on hemp derivatives conflict with congressional intent in the 2018 Farm Bill. The organization represents hemp businesses across 47 states and has opposed state-level restrictions on hemp-derived cannabinoids. General Counsel Jonathan Miller argued that the Farm Bill legalized all hemp derivatives and that states cannot prohibit federally legal agricultural products.

Drug Enforcement Administration

The Drug Enforcement Administration has issued conflicting guidance on the legal status of delta-8 THC and other semi-synthetic cannabinoids derived from hemp. In August 2020, the DEA published an interim final rule stating that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances" under 21 U.S.C. § 812. However, the agency has not actively enforced this interpretation against hemp-derived products, creating regulatory uncertainty. The DEA declined to comment on the Missouri litigation.

Legal and Regulatory Framework

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018 legalized hemp and hemp derivatives at the federal level, removing them from Schedule I of the Controlled Substances Act. Section 10113 of the Farm Bill, codified at 7 U.S.C. § 1639o, defines hemp as cannabis plants and derivatives containing no more than 0.3% delta-9 THC on a dry weight basis. Section 297A explicitly states that hemp is not a controlled substance under 21 U.S.C. § 802(6). The Farm Bill preserved state authority to regulate hemp production and commerce within state borders. Section 10114, codified at 7 U.S.C. § 1639p, provides that "nothing in this subchapter preempts or limits any law of a State or Indian Tribe that regulates the production of hemp" and allows states to prohibit hemp production entirely. However, the Farm Bill did not explicitly address whether states can prohibit specific hemp derivatives while allowing hemp cultivation and other hemp products. This ambiguity creates the central legal question in the Missouri litigation.

Controlled Substances Act

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I controlled substance but exempts hemp as defined by the Farm Bill. Section 802(16) defines marijuana as "all parts of the plant Cannabis sativa L." with exceptions for mature stalks, fiber, and other non-psychoactive components. The 2018 Farm Bill amended this definition to exclude hemp. Section 812 establishes five schedules of controlled substances based on abuse potential and medical utility. Schedule I substances, including marijuana, are defined as having high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. Tetrahydrocannabinols are listed in Schedule I under 21 CFR § 1308.11(d)(31). The DEA's August 2020 interim final rule stated that synthetically derived THC remains Schedule I regardless of source material. The agency defined synthetically derived as substances "obtained by chemical synthesis or by chemical modification of a natural starting material." This interpretation would classify delta-8 THC produced through isomerization of hemp-derived CBD as a controlled substance, contradicting the Farm Bill's legalization of all hemp derivatives.

Missouri Constitutional Amendment 3

Missouri Constitutional Amendment 3, approved by voters in November 2022, legalized adult-use marijuana but did not address hemp-derived products. Article XIV, Section 1 of the Missouri Constitution, as amended, provides that adults 21 and older may possess up to three ounces of marijuana and cultivate up to six flowering marijuana plants. The amendment directed the Department of Health and Senior Services to establish a comprehensive regulatory framework for marijuana businesses. Section 1(8) of Amendment 3 imposes a 6% tax on adult-use marijuana sales. Section 1(9) allocates tax revenue to expungement programs (first $5 million annually), veterans' services (first $10 million annually after expungement funding), and public defenders (remaining revenue). The amendment generated $98 million in tax revenue during the first full year of adult-use sales in 2023. The amendment defines marijuana as "all parts of the plant genus Cannabis" but includes an exception for "industrial hemp as defined and authorized under Missouri law." This language preserved the distinction between marijuana and hemp but did not define which hemp products are permissible.

Missouri Emergency Rulemaking Authority

Missouri Revised Statutes § 536.025 authorizes state agencies to issue emergency rules without public comment when "immediate danger to the public health, safety or welfare requires emergency action." Emergency rules take effect immediately upon filing with the Secretary of State and remain valid for 180 days. Agencies must simultaneously begin the standard rulemaking process to make emergency rules permanent. The statute requires agencies to make specific findings that an emergency exists and that the rule is necessary to address the immediate danger. Courts review emergency rules under an abuse of discretion standard, giving substantial deference to agency expertise in identifying public health threats. The Missouri Department of Health and Senior Services cited this authority in issuing the September 2024 emergency rule banning hemp-derived THC products. The department's findings referenced adverse event reports, lack of testing requirements, and availability to minors as immediate public health concerns justifying emergency action.

Commerce Clause Challenges

The dormant Commerce Clause, derived from Article I, Section 8 of the U.S. Constitution, prohibits states from discriminating against interstate commerce or imposing undue burdens on it. The Supreme Court established in City of Philadelphia v. New Jersey, 437 U.S. 617 (1978), that state laws favoring in-state economic interests over out-of-state competitors face heightened scrutiny and are generally unconstitutional unless justified by legitimate local concerns unrelated to economic protectionism. The hemp industry's federal lawsuit argues that Missouri's ban discriminates against interstate commerce in hemp-derived products to protect in-state marijuana licensees from competition. The complaint alleges that virtually all hemp-derived THC products sold in Missouri before the ban were manufactured out-of-state, while marijuana products are predominantly produced by Missouri licensees. Under Supreme Court precedent in Hunt v. Washington State Apple Advertising Commission, 432 U.S. 333 (1977), state laws that benefit local businesses by burdening out-of-state competitors violate the Commerce Clause even if facially neutral. The plaintiffs argue Missouri's ban fits this pattern by eliminating interstate hemp products while preserving the in-state marijuana market.

State-by-State Breakdown of Hemp THC Regulations

States with Comprehensive Bans

Fourteen states have enacted laws or regulations prohibiting delta-8 THC and other intoxicating hemp-derived cannabinoids as of July 2026.

State	Effective Date	Banned Substances	Enforcement Mechanism
Alaska	October 2021	Delta-8, Delta-10, THC-O	Controlled substance scheduling
Arkansas	April 2021	All synthetically derived THC	Controlled substance scheduling
Colorado	July 2022	Delta-8, Delta-10, THCA products	Hemp regulation
Delaware	June 2022	Delta-8, Delta-10, THC-O, HHC	Controlled substance scheduling
Idaho	April 2021	All THC isomers	Controlled substance law
Iowa	July 2023	Delta-8, Delta-10, THCA	Hemp regulation
Kentucky	January 2023	Delta-8, Delta-10, THC-O	Hemp regulation
Missouri	September 2024	All intoxicating hemp cannabinoids	Health department regulation
Montana	August 2021	Delta-8, Delta-10	Controlled substance scheduling
New York	November 2022	Delta-8, Delta-10, THC-O, HHC	Cannabis regulation
North Dakota	April 2021	All synthetically derived cannabinoids	Controlled substance scheduling
Rhode Island	July 2021	Delta-8, Delta-10	Controlled substance scheduling
Utah	May 2022	Delta-8, Delta-10, THC-O	Controlled substance scheduling
Vermont	June 2021	All synthetically derived THC	Controlled substance scheduling

States with Regulatory Frameworks

Seven states have implemented regulatory frameworks for hemp-derived THC products including age restrictions, testing requirements, and potency limits rather than outright bans. California established a regulatory framework in October 2023 requiring hemp-derived THC products to comply with the same testing, packaging, and labeling standards as marijuana products. Products must contain no more than 0.3% delta-9 THC per serving and be sold only through licensed cannabis retailers to adults 21 and older. Minnesota enacted legislation in May 2023 creating a regulatory framework for "edible cannabinoid products" derived from hemp. Products may contain up to 5mg THC per serving and 50mg per package, must be tested by accredited laboratories, and can be sold only to adults 21 and older through licensed retailers. Oregon requires hemp-derived THC products to be sold through the state's licensed marijuana retail system. The Oregon Liquor and Cannabis Commission issued rules in March 2024 requiring all inhalable and ingestible hemp products containing detectable THC to meet marijuana testing and packaging standards.

States with Pending Legislation

Legislatures in Texas, Florida, Georgia, North Carolina, and Tennessee considered bills to regulate or ban hemp-derived THC products during 2025-2026 sessions. Texas House Bill 447, introduced in January 2025, would have banned delta-8 THC and other intoxicating hemp products but failed to advance from committee. The bill faced opposition from hemp industry groups and rural agricultural interests. Texas remains one of the largest markets for hemp-derived products, with an estimated $400 million in annual sales. Florida considered Senate Bill 1698 in the 2026 legislative session, which would have created a regulatory framework for hemp-derived cannabinoid products including testing requirements and a 21+ age restriction. The bill passed the Senate but died in the House amid opposition from marijuana industry groups seeking a complete ban.

Market and Business Implications

Impact on Missouri Marijuana Licensees

Licensed marijuana operators reported increased sales following the September 2024 hemp product ban, with statewide adult-use marijuana sales rising 18% in the fourth quarter of 2024 compared to the third quarter. Missouri dispensaries sold $312 million in adult-use marijuana during October-December 2024, up from $264 million in July-September 2024, according to Department of Health and Senior Services data. Industry representatives attributed the increase partly to consumers switching from banned hemp products to licensed marijuana. The Missouri Cannabis Trade Association estimated that hemp-derived products captured 15-20% of the total cannabinoid market in Missouri before the ban, representing approximately $200-250 million in annual sales that competed directly with licensed marijuana products. Licensed operators argued the ban restored market conditions voters intended when approving Amendment 3. However, licensed marijuana prices remain significantly higher than pre-ban hemp product prices. The average price per milligram of THC in Missouri dispensaries was $0.18 in June 2026, compared to an estimated $0.03-0.05 per milligram for delta-8 THC products before the ban. This price differential has driven some consumers to neighboring states or online sources.

Hemp Industry Economic Losses

The Missouri hemp industry estimates direct economic losses exceeding $200 million annually from the ban, with additional impacts on agricultural production and manufacturing. Approximately 2,500 Missouri retailers sold hemp-derived THC products before September 2024, including 800 independent smoke shops and CBD stores, 1,200 gas stations and convenience stores, and 500 online retailers shipping from Missouri locations. The Missouri Hemp Trade Association estimates 3,000 job losses resulted from the ban, including retail positions, manufacturing jobs at hemp processing facilities, and distribution roles. Five hemp extraction facilities in Missouri closed or significantly reduced operations following the ban, according to industry surveys. Missouri hemp farmers cultivated approximately 8,000 acres of hemp in 2023, with roughly 40% grown for cannabinoid extraction. The ban reduced demand for high-cannabinoid hemp biomass, causing prices to fall from an average of $300 per pound in 2023 to $75 per pound in 2025. Several farmers exited hemp production or shifted to fiber and grain varieties.

Interstate Commerce Patterns

The hemp-derived THC market operates primarily through interstate commerce, with most products manufactured in states with established hemp industries and shipped to consumer markets nationwide. Major hemp extraction and manufacturing facilities are concentrated in Colorado, Oregon, Kentucky, North Carolina, and Tennessee. These facilities process hemp biomass into CBD isolate, then convert it to delta-8 THC and other cannabinoids through chemical synthesis. Missouri imported an estimated 95% of hemp-derived THC products sold within the state before the ban, according to industry data. This interstate commerce pattern forms the basis for the Commerce Clause challenge in the federal lawsuit. Plaintiffs argue that Missouri's ban discriminates against out-of-state hemp manufacturers while protecting in-state marijuana producers. The ban has redirected some consumer purchasing to neighboring states. Kansas, which has not banned hemp-derived products, reported increased sales at retailers near the Missouri border following Missouri's prohibition. Online sales from out-of-state retailers to Missouri consumers continue despite the ban, though enforcement against individual consumers has been minimal.

Investment and Capital Markets

The regulatory uncertainty surrounding hemp-derived cannabinoids has constrained investment in the sector, with venture capital funding for hemp companies falling 62% in 2025 compared to 2023. According to cannabis investment tracking firm Viridian Capital Advisors, hemp companies raised $127 million in 2025, down from $334 million in 2023. State-level bans and pending federal regulatory action have made hemp-derived cannabinoid businesses less attractive to institutional investors. Multi-state operators in the licensed marijuana industry have generally avoided hemp-derived products due to regulatory risks and potential conflicts with state licenses. However, several MSOs including Curaleaf and Trulieve have advocated for state-level hemp bans to eliminate competition. Industry analysts estimate that hemp product bans in major markets could increase licensed marijuana sales by 10-15%, potentially adding $500 million to $1 billion in annual revenue for MSOs nationally.

What Experts Say

Legal scholars and cannabis policy experts have offered divergent views on the constitutional and policy questions raised by state hemp product bans. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," stated in a June 2026 interview that the Commerce Clause challenge faces significant obstacles. According to Mikos, the Farm Bill's preservation of state regulatory authority over hemp likely permits states to ban specific hemp products, even if such bans incidentally burden interstate commerce. He noted that the Supreme Court has historically given states broad authority to regulate intoxicating substances under their police powers. However, Sam Kamin, professor at University of Denver Sturm College of Law, argued in testimony before the Colorado legislature that state bans on federally legal hemp products raise serious preemption concerns. According to Kamin, Congress clearly intended to legalize hemp and all its derivatives in the 2018 Farm Bill, and state bans that effectively nullify this federal policy may exceed state authority. He suggested that states have less restrictive alternatives available, such as age restrictions and testing requirements. Shawn Hauser, partner at Vicente Sederberg LLP and chair of the firm's hemp and cannabinoid practice, stated in a July 2026 analysis that the Missouri ban represents a test case for whether states can use health and safety regulations to eliminate federally legal products that compete with state-licensed industries. According to Hauser, if courts uphold Missouri's approach, other states with marijuana programs will likely follow suit, effectively creating a patchwork where hemp-derived cannabinoids are legal only in states without adult-use marijuana markets. Dale Hunt, former chief of the Drug Enforcement Administration's Cannabis and Chemical Diversion Section, said in a May 2026 podcast interview that the DEA's position on synthetically derived cannabinoids remains that they are Schedule I controlled substances regardless of source material. According to Hunt, the agency views chemical conversion of CBD to delta-8 THC as synthesis of a controlled substance, not extraction of a legal hemp derivative. However, he acknowledged that the DEA has not prioritized enforcement against hemp-derived products due to resource constraints and the Farm Bill's ambiguity. Douglas Berman, professor at Ohio State University Moritz College of Law and editor of the Marijuana Law, Policy, and Reform blog, wrote in a June 2026 post that the Missouri litigation highlights fundamental tensions in federal cannabis policy. According to Berman, Congress created the current conflict by legalizing hemp without clearly addressing intoxicating derivatives, while maintaining marijuana prohibition. He argued that comprehensive federal cannabis reform is necessary to resolve these contradictions.

What's Next

Federal Litigation Timeline

The Missouri hemp ban federal lawsuit will proceed through standard civil litigation stages, with key decisions expected in late 2026 and early 2027. The defendants filed a motion to dismiss on August 15, 2026, arguing that the complaint fails to state a claim under the Commerce Clause and that Missouri's ban is a valid exercise of police power authority preserved by the Farm Bill. Plaintiffs' response to the motion to dismiss is due September 15, 2026. If the court denies the motion to dismiss, discovery would likely extend through early 2027, with depositions of state officials, industry representatives, and expert witnesses. Plaintiffs are expected to seek a preliminary injunction blocking enforcement of the ban pending final resolution of the case. A preliminary injunction hearing could occur in late 2026. The case could reach the U.S. Court of Appeals for the Eighth Circuit by mid-2027 if either party appeals the district court's ruling. Given the national significance of the legal issues, the case has potential to reach the U.S. Supreme Court, though the Court accepts only a small fraction of petitions for certiorari.

Potential Federal Regulatory Action

The U.S. Food and Drug Administration has indicated it may propose regulations for hemp-derived CBD and other cannabinoids, though no timeline has been announced. The FDA sent a report to Congress in January 2023 stating that it lacks sufficient data to establish a regulatory framework for CBD products and requesting additional authority from Congress. The agency has issued warning letters to companies making unsubstantiated health claims about CBD products but has not taken enforcement action against delta-8 THC or other intoxicating hemp derivatives. Congressional legislation to clarify the legal status of hemp-derived cannabinoids has been introduced but not advanced. The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2025, introduced in the House in March 2025, would direct the FDA to establish regulations for hemp-derived cannabinoid products including testing, labeling, and potency standards. The bill remained in committee as of July 2026 with limited prospects for passage. The DEA has not issued updated guidance on synthetically derived cannabinoids since its August 2020 interim final rule. Agency officials have stated informally that enforcement priorities focus on fentanyl, methamphetamine, and other synthetic opioids rather than hemp-derived products, but the agency has not formally changed its legal position that synthetically derived THC remains Schedule I.

State Legislative Trends

Additional states are expected to consider hemp-derived cannabinoid restrictions during 2027